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\s=b\Cumulative risks of developing extra-
pyramidal signs, psychosis, and myoclonus
in the course of Alzheimer's disease (AD)
were estimated in 72 patients with probable
AD by the Kaplan-Meier survival method. The
cumulative risk functions were found to in-
crease at different rates for different signs as
AD progressed. Comparisons of the cumula-
tive risk functions revealed that in the early
stages of AD, extrapyramidal signs and psy-
chosis were more likely to develop than myo-
clonus. As AD progressed, the risk of devel-
oping myoclonus became as great as that of
developing the other two signs. This study
suggests that extrapyramidal signs, psycho-
sis, and myoclonus represent developmen-
tal features that mark the progression of AD,
rather than indicators of disease subtypes.
The estimated cumulative risk functions set
a reasonable expectation for the timing and
likelihood of the emergence of the clinical
signs. This, in turn, might aid in disease prog-
nosis because the biological bases of these
signs have been established and they have
been shown to be predictive of other markers
of disease course.
(Aren Neurol. 1991;48:1141-1143)
 portion of patients diagnosed
"^ with probable Alzheimer's disease(pAD) develop extrapyramidal signs,
psychosis, or myoclonus during the dis¬
ease.1"7 These signs have previously
been shown to be good predictors of
disease progression: patients develop¬
ing one ofthe signs by their first clinical
evaluation tend to deteriorate to specif¬
ic cognitive and functional end points
sooner than those without these signs.8,9
The same patients also have a higher
risk of mortality.1" However, these
signs are no more predictors than out¬
comes by their nature, and knowing
that myoclonus predicts faster cogni¬
tive decline or death still begs the ques¬
tion of how likely it is that a patient will
develop myoclonus at any particular
point in disease progression. This study
attempted to address this question as
well as to determine if different signs
tend to emerge at different points in the
disease course.
We define risk, throughout the arti¬
cle, as the probability that a patient de¬
velops a clinical sign before time t. This
is commonly known as the cumulative
distribution function (F(t)), or simply
the cumulative risk, and can be estimat¬
ed by the Kaplan-Meier survival meth¬
od."
SUBJECTS AND METHODS
Subjects
Seventy-two patients (34 men, 38 women)
met the Diagnostic and Statistical Manual
of Mental Disorders-Ill-Revised criteria for
primary degenerative dementia and the
National Institute of Neurological Disorders
and Stroke-Alzheimer's Disease and Relat¬
ed Disorders Association criteria for proba¬
ble AD.1'1 This is the same cohort of patients
that was used in previous studies of the pre¬
dictive value of clinical signs,1'8"1" and consist¬
ed of a consecutive series ofpatients present¬
ing for evaluation of dementia in a clinical
practice. Inclusion in the study was not de¬
pendent on disease severity or the presence
or absence of symptoms.
Mean age at onset ofthe disease was 64.11(SD = 9.39) years. Mean duration of illness by
first clinical evaluation was 2.95 (SD = 1.63)
years.
Patients were followed up for an average
of 5.05 years (SD = 2.29) and evaluated at
least twice, with a minimum interval of 6
months between evaluations. Twenty-nine
patients were followed up to death; autopsy
was obtained in eight patients and AD was
confirmed in all.
Procedures
All neurologic and psychiatric evaluations
were conducted by the same investigator(R.M.).
Extrapyramidal Signs and Myo¬
clonus.—Extrapyramidal signs (EPSs), in¬
cluding tremor, rigidity, bradykinesia, gait,
postural change, and masked faces, were rat¬
ed using selected items from the Unified Par¬
kinson's Disease Evaluation." A patient was
considered to have EPS if any rated sign was
present. All medications were recorded.
If a patient took any medication that might
have caused EPS, the occurrence of these
signs was not counted in the analyses. This
conservative approach limits statistical pow¬
er to some degree but ensures that only true
EPSs are evaluated.
Myoclonus was rated as absent, present
with sleep only, present with startle only, or
present while awake or asleep.
Psychosis.—All patients and available
family members or informants were inter¬
viewed in a semistructured fashion to assess
the presence of psychiatric symptoms, using
the Diagnostic and Statistical Manual of
Mental Disorders-Ill-Revised as a guide¬
line. The presence of persistent hallucina¬
tions, illusions, or delusions was sufficient to
rate a patient as having psychosis.
Determining Onset of AD.—At the first
visit, the patients and reliable informants
were interviewed to determine the date at
which the patient first met the criteria for the
diagnosis of pAD. The reliability of our onset
assessments was confirmed using standard¬
ized interview techniques.10
Determining Onset of a Clinical Sign.—
Onset of a clinical sign was estimated as the
date when the sign was first noted by a neu¬
rologist on one of the patient's visits. Al¬
though this estimation tended to bias the
actual onset toward a later date, it was as¬
sumed that the bias existed to the same ex¬
tent in estimates of all three clinical signs
and, therefore, would only affect the abso¬
lute onset dates ofthe signs but not the com¬
parisons between them.
Analysis
Kaplan-Meier survival analysis11'16 was
used to estimate the cumulative risks of de¬
veloping the clinical signs during the disease.
The SAS LIFETEST procedure was used in
the computing of the cumulative risk func¬
tions." Binomial tests were employed to
compare the times of occurrence ofthe signs.
In addition, the percentages of patients who
evidenced the clinical signs (prevalence) as
well as the number ofpatients who developed
them (incidence)18 were calculated. These
values were not meant to estimate the popu¬
lation prevalence and incidence parameters,
but to estimate how frequently the signs
were noted in this particular sample.
RESULTS
Survival Analyses
Kaplan-Meier survival analysis was
employed to estimate the cumulative
risk for developing each clinical sign by
defining the first occurrence of a sign as
the end point. The cumulative risk func¬
tions for the three signs over the disease
period were then compared. As shown
in the Figure, the cumulative risk of
developing EPS resembled that of de¬
veloping psychosis, and both were
greater than the cumulative risk of de¬
veloping myoclonus. As the disease pro¬
gressed, the risk of developing myo¬
clonus became as great as those of
developing EPS and psychosis. Wilcox-
on's rank sum test yielded a
 2 of 7.34,
 
=
.025 (The test assumes indepen¬
dence among the cumulative risk func¬
tions under comparison, which was not
the condition in our study since some
patients have developed more than one
sign and the three cumulative risk func¬
tions were based on overlapping sub¬jects. The test, however, can be used as
a conservative one to demonstrate the
difference among the cumulative risk
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functions). These results suggested
that EPS and psychosis tended to
emerge earlier than myoclonus in the
course of AD.
Binomial Tests
To further support the observation
that EPS and psychosis tended to
emerge earlier than myoclonus, the
number of patients in whom the occur¬
rence of each sign preceded another was
examined in two-tailed binomial tests.
To prevent an increase of type 1 error
rate in multiple tests, Bonferroni cor¬
rection was applied to yield an adjusted
significance level of .017 (.05/3). The
EPS occurred before myoclonus in 30 of
43 patients (z = 2.44,  =.015), psycho¬
sis occurred before myoclonus in 30 of 44
patients (z = 2.26,  =.024), while EPS
occurred before psychosis in 22 of 41
patients (z = 0.38,  = .76). These re¬
sults are, therefore, consistent with the
findings obtained in the survival
analyses.
Presence and Occurrence of the
Three Clinical Signs
The percentage ofpatients displaying
EPS, psychosis, and myoclonus at the
first clinical evaluation (prevalence)
was 27.8%, 25%, and 6.9%, respective¬
ly. Overall, the percentage of patients
displaying clinical signs by the last clini¬
cal visit were 51%, 47%, and 39% for
EPS, psychosis, and myoclonus, re¬
spectively. The percentage of patients
without a clinical sign at the first evalua¬
tion who developed one during follow-
up (incidence) was 32.7% for EPS,
29.7% for psychosis, and 34.3% for myo¬
clonus. Because patients were followed
up for different lengths of time, we took
the total number of new cases during
the follow-up period and divided it by
the sum of follow-up time for all patients
being followed up. The result was multi¬
plied by 1000 and expressed as cases per
1000-person years. The incidence rates
from the first to the last evaluation are
101, 102, and 115 cases per 1000-person
years for EPS, psychosis, and myo¬
clonus, respectively (Table).
COMMENT
In this study, we have taken a differ¬
ent perspective on EPS, psychosis, and
myoclonus, viewing them as disease
outcomes rather than predictors. We
found that the cumulative risks of devel¬
oping EPS, psychosis, and myoclonus
are different during the course of
 
AD.
It appears that a patient with pAD is
more likely to develop EPS or psychosis
than myoclonus during the first few
years of the disease. As disease pro-
Cumulative Risk
EPS
Psychosis
Myoclonus
10 11 12 13 14 15 16
Years From Estimated Onset of pAD Until Inception of a Sign
Cumulative risks of developing extrapyramidal signs (EPS), psychosis, or myoclonus in the course
of probable Alzheimer's disease (pAD), estimated from the Kaplan-Meier survival analysis.
Prevalence by First Clinical Evaluation, Incidence, and Incidence Rate (Cases per
1000-Person Years) During Follow-up Period, and Prevalence by Last Clinical
Evaluation for EPs, Psychosis, and Myoclonus*
Prevalence
at First
Clinical
Evaluation
%
Incidence
During
Follow-up
Period,
%
Incidence
Rate During
Follow-up
Period
(per 1000
person years)
Prevalence
at Last
Clinical
Evaluation,
%
EPSs 27.78 32 69 101 51.39
Psychosis 29.63
Myoclonus 6.94 34.33 115 38.89
EPSs indicates extrapyramidal signs.
'Values are intended to be descriptive of the study group only, not of the general population.
gresses, myoclonus becomes as likely to
occur as the other signs. The estimated
cumulative risk functions provide a rea¬
sonable expectation ofhow likely it is for
a clinical sign to emerge at any point in
the disease. This, combined with the
demonstrated predictive value of the
signs, should help in planning care and
treatment of patients.
We observed a frequency of 6.9% for
myoclonus by the first clinical evalua¬
tion, which is similar to 6.2% reported
by Chui et al3 their cross-sectional
study. In addition, we found that myo¬
clonus has a high incidence rate but a
low prevalence rate. This suggests that
myoclonus is not rare in
 
AD; perhaps
because the duration of pAD is de¬
creased after its appearance,1" preva¬
lence is low. This is not true for EPS and
psychosis, however. In fact, when the
incidence rates are compared, it is myo¬
clonus that seems to have a higher fre¬
quency ofoccurrence than the other two
clinical signs.
There are some caveats to the inter¬
pretation ofthe results. First, in deter¬
mining the onset of clinical signs, we
made an assumption that a sign is nonre-
versible once it emerges. Although cli¬
nicians generally agree that EPS is not
reversible, subtle EPS may be noted on
one visit but not on a following visit, or
vice versa, which makes the onset esti¬
mate somewhat problematic. An ideal
way of resolving this problem is to ex¬
amine a patient's EPS ratings on succes¬
sive visits and determine when the sign
was consistently noted on two or more
consecutive visits. Unfortunately, our
data do not contain enough follow-ups to
allow for such a clarification. Psychosis
faces even a greater difficulty, since the
nonreversibility assumption is usually
not justified. On the other hand, myo¬
clonus seems to enjoy greater certainty
in its detection and nonreversibility can
be more safely assumed. A related set of
issues that cannot be addressed with
these data is whether, in patients with
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one EPS, others tend to develop in time.
Similarly, the relative importance of
each EPS in our incidence figures is not
evaluated due to restricted power.
Second, it may be argued that our
sample has included unusual cases and
was biased. However, our sample does
not seem to be more biased than other
similar studies because the prevalences
ofthe three signs as we observed are not
higher than those observed by others.3"
519"21 It is possible, of course that the
referral patterns of patients to our cen¬
ter differ from those to other centers in
some systematic way. For this reason,
confirmatory studies across centers
would help to confirm the natural histo¬
ry of the clinical signs as presented
here.
Extrapyramidal signs must be distin¬
guished from unrelated manifestations
of AD. For example, a patient may be
apathetic, but facial immobility will be
apparent even when his interest is en¬
gaged. A patient may take uncertain
steps because of confusion over his/her
destination, but this cannot be confused
with the shuffling gait observed while
the patient is walking several feet to a
certain destination. Similarly, paucity
of movement unrelated to EPS must be
distinguished from bradykinesia during
elicited movements. These distinctions
require clinical judgment. In this study,
reliability of these ratings is ensured by
the use of only a single rater.
The results imply that EPS, psycho¬
sis, and myoclonus are developmental
markers of AD that every patient will
eventually develop if they live long
enough. This view is not consistent with
the concept that these signs define sub¬
types of pAD.1,2·3'6·7,22 According to the
subtype concept, patients developing
myoclonus in the course of AD form a
distinct group, which differs pathologi¬
cally, and perhaps etiologically as well,
from the group who develop EPS or
other clinical signs. The concept implies
mutual exclusiveness of the subtypes.
It also suggests that some patients will
develop myoclonus, for example, while
others will not. Our data show that some
patients developed more than one clini¬
cal sign during the disease, eg, myo¬
clonus as well as EPS. They also sug¬
gest that it is probable that every
patient will eventually develop myo¬
clonus, but with the risk differing dur¬
ing the course of disease.
We suggest that it might be more
appropriate to view the various clinical
signs, be they EPS, psychosis, myo¬
clonus, specific levels of functional or
cognitive deterioration, or even death,
as different disease markers or out¬
comes that emerge at different stages of
the disease. Given that individuals are
born with somewhat different biological
makeups, it is reasonable to tolerate a
certain degree of variability as to when
each sign will emerge in an individual
patient. In other words, clinical hetero¬
geneity need not be interpreted as indi¬
cation of disease subtypes; rather, it
may be explained as reflecting variation
in a probability distribution whose pa¬
rameters are estimable. An advantage
of this view is that each disease feature
is allowed to emerge with different
probabilities at different times, and its
relationship with other disease features
can be properly assessed. For example,
some disease features may have a high¬
er probability of occurring earlier than
others. Knowledge of this can help de¬
termine the temporal order of occur¬
rences ofthe various disease features in
the course of AD. In addition, one can
examine how the occurrence of one dis¬
ease feature affects, or is affected by,
the occurrence of another disease fea¬
ture. Our previous work*1" on the three
clinical signs as predictors of cognitive
and functional deterioration as well as
mortality constitutes an attempt along
this line. Our article provides a broader
view of the issue in the sense that the
clinical signs, when looked on as devel¬
opmental markers, can serve as out¬
comes just as well as serving as
predictors.
It is important to note that the proba¬
bilistic view adopted here does not
strictly rule out the concept ofsubtypes.
For instance, it is conceivable that a
certain group of patients, for example
those with a family history of AD, may
have a higher risk of developing a par¬
ticular disease feature than another
group.23,24 In other words, there can be
different disease courses for different
disease subtypes, with each course be¬
ing described in the same probabilistic
manner. On the other hand, the identifi¬
cation of a subtype should be evaluated
against a probabilistic view so that a
subtype is not merely reflecting sample
heterogeneity or natural individual
differences.
As the temporal probability distribu¬
tions of sufficient disease outcomes are
determined and the relationship among
them examined, a more complete pic¬
ture of the natural history of AD may
start to emerge. It may, then, become
conceivable to predict the course of an
individual's disease based on the pres¬
ence or absence of any of these signs.
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